C. Orkin

Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection

G. Cooke, G. Dore, C. Orkin, 2018, Journal of viral hepatitis.

Authors' response to Drs Scourfield, Jackson and Nelson

B. Gazzard, C. Leen, C. Sabin, 2011 .

The prevalence of hepatitis C virus (HCV) infection in HIV‐positive individuals in the UK – trends in HCV testing and the impact of HCV on HIV treatment outcomes

B. Gazzard, C. Leen, D. Pillay, 2009, Journal of viral hepatitis.

Twenty‐four‐week efficacy and safety of switching virologically suppressed HIV‐1‐infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION)

K. Arastéh, A. Quinson, J. Livrozet, 2012, HIV medicine.

Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study *

B. Gazzard, C. Leen, D. Pillay, 2010, HIV medicine.

Week 96 analysis of rilpivirine or efavirenz in HIV‐1‐infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double‐blind trials

C. Orkin, N. Clumeck, J. Molina, 2014, HIV medicine.

Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT)

J. Ainsworth, M. Gompels, A. Arenas-Pinto, 2024, EClinicalMedicine.